The division of Biopharmaceutics aims to develop and test new therapeutic approaches to treat cardiovascular diseases, such as heart infarcts and stroke. Cardiovascular disease is still the major cause of death in the Western society and the main underlying pathology of cardiovascular disease is atherosclerosis. Atherosclerosis is the process that leads to the narrowing of medium and large-sized arteries and this the narrowing of the arteries, the formation of atherosclerotic plaques or lesions, results from the complex interaction between genes involved in lipoprotein metabolism and inflammation. In the later stages of atherosclerosis the lesions may rupture which leads to thrombosis and this may leads to brain or heart infarcts. It is well-established that genetic predisposition for atherosclerosis is related to dyslipidemia and inflammatory responses.
Within the division of Biopharmaceutics research focusses on the role of dyslipidemia and a derailed immune responses inflammation in the initiation, progression and rupture of the atherosclerotic plaques. Our research aims to identify genes responsible for the occurrence of cardiovascular disease that can subsequently be used to serve as drug targets. Therapeutic approaches focus on the use of biologics to develop novel experimental therapies to prevent and/or treat cardiovascular disease. The therapeutic approaches involve targeted delivery of drugs, use of monoclonal antibodies and vaccination protocols to treat atherosclerosis.
- Erik van Kampen publishes in the Journal of Leukocyte Biology: The effects of poor eating habits persist even after diet is improved
- Read more
- Miranda van Eck hoogleraar Cardio Vascular & Metabolomic Therapeutics
Miranda van Eck is benoemd tot hoogleraar Cardio Vascular & Metabolomic Therapeutics bij het Leiden Academic Center for Drug Research (LACDR) van de faculteit der Wiskunde en Natuurwetenschappen.
- Read more
- Johan Kuiper: vaccin tegen aderverkalking
- Function human receptor for good cholesterol unmasked
HDL is known as the “good cholesterol”: it lowers the chance of developing cardiovascular disease. Some families display naturally high levels of HDL in their blood. Research on the underlying causes of genetically high HDL cholesterol is important for the development of new medicines that can increase HDL levels in the blood.
- Read more